Ontology of Drug Adverse Events

Last uploaded: January 12, 2019

Id	http://evs.nci.nih.gov/ftp1/NDF-RT/NDF-RT.owl#N0000006700 http://evs.nci.nih.gov/ftp1/NDF-RT/NDF-RT.owl#N0000006700
Preferred Name	Levodopa [Chemical/Ingredient]
Type	http://www.w3.org/2002/07/owl#Class

label	Levodopa [Chemical/Ingredient]
prefLabel	Levodopa [Chemical/Ingredient]
NUI	N0000006700
Synonym	3-Hydroxy-L-tyrosine L-3,4-Dihydroxyphenylalanine L-Dopa
code	C23748
prefixIRI	NDF-RT:N0000006700
RxNorm_CUI	6375
subClassOf	http://evs.nci.nih.gov/ftp1/NDF-RT/NDF-RT.owl#N0000007917
imported from	http://evs.nci.nih.gov/ftp1/NDF-RT/NDF-RT.owl
MeSH_CUI	M0012434
MeSH_DUI	D007980
type	http://www.w3.org/2002/07/owl#Class
MeSH_Name	Levodopa
UMLS_CUI	C0023570
RxNorm_Name	Levodopa
Display_Name	Levodopa
MeSH_Definition	The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.

Delete	Subject	Author	Type	Created
No notes to display